@article {Luo2020.06.01.20086025, author = {Huanyuan Luo and Songqiao Liu and Yuancheng Wang and Penelope A. Phillips-Howard and Yi Yang and Shenghong Ju and Duolao Wang}, title = {Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multi-center cohort study}, elocation-id = {2020.06.01.20086025}, year = {2020}, doi = {10.1101/2020.06.01.20086025}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives To determine the age-specific clinical presentations and incidence of adverse outcomes among patients with COVID-19 in Jiangsu, China.Design and setting This is a retrospective, multi-center cohort study performed at twenty-four hospitals in Jiangsu, China.Participants From January 10 to March 15, 2020, 625 patients with COVID-19 were involved.Results Of the 625 patients (median age, 46 years; 329 [52.6\%] males), 37 (5.9\%) were children (18 years or less), 261 (40\%) young adults (19-44 years), 248 (39.7\%) middle-aged adults (45-64 years), and 79 (12.6\%) elderly (65 years or more). The incidence of hypertension, coronary heart disease, chronic obstructive pulmonary disease, and diabetes comorbidities increased with age (trend test, P \<.0001, P = 0.0003, P \<.0001, and P \<.0001 respectively). Fever, cough, and shortness of breath occurred more commonly among older patients, especially the elderly, compared to children (Chi-square test, P = 0.0008, 0.0146, and 0.0282, respectively). The quadrant score and pulmonary opacity score increased with age (trend test, both P \<.0001). Older patients had significantly more abnormal values in many laboratory parameters than younger patients. Elderly patients contributed the highest proportion of severe or critically-ill cases (33.0\%, Chi-square test P \< 0.001), intensive care unit (ICU) (35.4\%, Chi-square test P \< 0.001), and respiratory failure (31.6\%, Chi-square test P = 0.0266), and longest hospital stay (21 days, ANOVA-test P \< 0.001).Conclusions Elderly (>=65) patients with COVID-19 had the highest risk of severe or critical illness, intensive care use, respiratory failure, and the longest hospital stay, which may be due partly to that they had higher incidence of comorbidities and poor immune responses to COVID-19.Strengths and limitations of this study The cohort consists of almost all COVID-19 patients in Jiangsu province with a population over 80 million and its results should be representative of the patient population in the whole province and with a wide range of disease severity, therefore the results are subject to less selection bias.The study includes imported and local cases and could study patients with different types of exposures.The relative short follow-up time and a very small proportion of patients who remained in hospital after the 14-day follow-up period yield incomplete estimates for disease severity and clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the research Grant 2020YFC0843700 67 from Ministry of Science and Technology of the People Republic of China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval: The study was approved by the Ethics Committee of Zhongda Hospital Affiliated to Southeast University (2020ZDSYLL013 P01 and 2020ZDSYLL019 P01). Patient consent: Informed consent was waived due to the emergent pandemic.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are freely available within the appendices. No additional data available.}, URL = {https://www.medrxiv.org/content/early/2020/06/02/2020.06.01.20086025}, eprint = {https://www.medrxiv.org/content/early/2020/06/02/2020.06.01.20086025.full.pdf}, journal = {medRxiv} }